At the gene expression level, the PAM50 assay1,2 has identified and intensively studied up to 4 intrinsic subtypes within HR+/HER2− breast cancer (i.e., Luminal A, Luminal B, HER2-enriched and Basal-like3–7. Here, ERBB2 is linked to breast carcinoma.